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PERSPECTIVES IN RENAL MEDICINE
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Increased secretion of parathyroid hormone (PTH) is an invari-
able and early consequence of chronic renal failure, and its
pathogenesis has engaged a great deal of attention. The rate of
hormone secretion by the parathyroid, as of any endocrine gland,
is the product of the average rate of hormone secretion by each
individual cell and the total number of participating cells, but
much more attention has been given to the regulation of hormone
secretion than to the regulation of cell number [1J. Although the
main physiologic stimulus to PTH hypersecretion is hypocalcemia,
the response to a particular calcium level depends on the secre-
tory set-point. This is usually defined arbitrarily as the calcium
concentration corresponding to 50% suppression of PTH secre-
tion [21, but a more physiologic definition is the target value for
the calcium homeostatic system [3]. The relationship between
calcium and PTH is influenced in a complex manner by a low
calcitriol level, which is an independent stimulus to PTH secretion
[1—3]. The effect of a raised plasma phosphate is partly the result
of reciprocal changes in calcium and calcitriol levels, but phos-
phate can also stimulate PTH secretion directly [4—61. Each of the
three primary factors can be altered in chronic renal failure, and
their relative importance continues to be debated [7, 8], but the
role of parathyroid size is still often ignored. I will present the
evidence for parathyroid enlargement, including both hypertro-
phy and hyperplasia, as a major determinant of PTH hypersecre-
tion, review what is known about parathyroid cell proliferation
and turnover and how it is disturbed in renal failure, and consider
the therapeutic implications of the material presented.
THE IMPORTANCE OF PARATHYROID SIZE
In 1966, Stanbury and Lumb reviewed all available reports of
total parathyroid weight at autopsy in subjects dying with chronic
renal failure, and not selected with respect to the condition of
their bones [9]. In 119 cases, the values were log-normally
distributed, and the geometric mean weight was 0.187 (x/--2.23)g,
a relative increase of 67%, and the range was 0.045 g to 0.891 g [11
By contrast, in 26 subjects with histologic evidence of osteitis
fibrosa, the specific bone disease of hyperparathyroidism [10], the
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geometric mean weight was 3.52 (xI±2.35)g, about 20 times
greater, with range 0.78 g to 12.0 g [1]. There was only minimal
overlap, and total parathyroid weight was less than 1.0 g in all
patients without osteitis fibrosa, and greater than 1.0 g in almost
all patients with osteitis fibrosa [9]. Both the geometric mean and
range were much the same as for single adenomas causing osteitis
fibrosa in primary hyperparathyroidism [1, 11]. More recently,
similar values for geometric mean and range of total excised
weight have been found in patients with chronic renal failure
needing parathyroid surgery [12, 13], although these values will
reflect both historical changes in medical treatment and local
variations in surgical policy [1].
To those familiar with these data, it has always seemed obvious
that parathyroid size was the major determinant of the severity of
PTH hypersecretion in patients with chronic renal failure, and
that this relationship underlay both the justification and the
success of parathyroid resection in such patients [8, 13]. However,
evidence for this has remained indirect and circumstantial, be-
cause of the difficulty of measuring parathyroid size accurately
during life by noninvasive means. Radiologists have devised a
variety of procedures for parathyroid localization but have shown
little interest in size, reflecting the needs of their surgical col-
leagues. For studying pathogenesis and monitoring the effects of
medical treatment, the emphasis is just the opposite: size is
paramount and location largely irrelevant! For this purpose,
ultrasonography, with careful attention to many technical require-
ments, has been the most successful technique. In some hands,
this method has been sufficiently sensitive to detect the increase in
parathyroid volume brought about by lithium administration [14],
and the decrease brought about by pulsed administration of
la-hydroxylated derivatives of vitamin D [15]. More recently,
ultrasonography has been used to demonstrate a significant
relationship between parathyroid volume and dynamic indices of
PTH hypersecretion [16], the first time that this has been accom-
plished.
The importance of parathyroid cell number, as a determinant of
total PTFI secretion rate and plasma calcium level, was demon-
strated experimentally in 1966 [171 and deduced from a theoret-
ical model in 1969 [18]. Further refinement of the model led to
several important conclusions [1, 19]. First, an increase in cell
number has a smaller effect on PTH secretion than the same
relative increase in secretory set-point, but cell number can
increase over a much wider range. Second, the effect of cell
number on PTH secretion and plasma calcium is magnified by, but
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does not require, a non-suppressible component to PTH secre-
tion. Third, the biological advantage of operating on the central
steep portion of the sigmoid curve relating PTH secretion to
calcium, which is the ability to defend against both hyper- and
hypocalcemia [3, 20], is best preserved if both cell number and
secretory set-point are increased, as in most patients with primary
hyperparathyroidism. As predicted by the model, there is a highly
significant correlation between parathyroid tumor size and plasma
calcium with an average r value of about 0.6, ranging from 0.4 to
0.8 in different series [1]. The correlation between tumor weight
and circulating PTH level was improved by including ultrastruc-
tural indices of hormone secretion [211. The most impressive
correlation (r = 0.98)was found between parathyroid volume and
stimulated PTH secretion in patients with post-transplant hyper-
calcemia [22].
As the importance of parathyroid size has become more widely
recognized, so has more investigative attention been given to the
mechanisms underlying parathyroid enlargement. As with any
organ, it is important to distinguish between increased cell volume
(hypertrophy) and increased cell number (hyperplasia). Hypertro-
phy of both cells and nuclei accompanies increased hormone
secretion [23—25], but the increases are generally less than two-
fold, and the changes are completely reversible when the stimulus
to increased hormone secretion is removed [25, 26]. Hyperplasia
is much slower to develop, the changes can be of much larger
magnitude, and they are rarely reversible, even long after the
stimulus is removed [25, 26]. Most early work, including a classic
paper on dietary phosphate intake [27], reported only parathyroid
volume, and only recently has it been demonstrated that phos-
phate administration increases parathyroid cell number, as the
result of increased cell division [25, 28]. Since hyperplasia rather
than hypertrophy is the major determinant of parathyroid en-
largement in chronic renal failure, the regulation of normal and
abnormal cell proliferation, rather than the regulation of normal
and abnormal hormone secretion, is the key to the understanding
of uremic hyperparathyroidism [11.
PARATHYROID CELL PROLIFERATION AND ITS
REGULATION
From the standpoint of cell kinetics, there are two major classes
of tissue [29, 30]. In those with high turnover, cells of short life
span are continually replaced from a population of self-replicating
stem cells, that in the skin and intestinal mucosa, but not in the
bone marrow, are anatomically as well as functionally segregated.
In tissues with low turnover there are no separate stem cells, and
all cells have the capability not only of expressing the differenti-
ated function appropriate to the tissue, but, if the need arises, of
interrupting this function in order to enter the cell cycle. Such
tissues are known as discontinuously replicating, or conditionally
renewing [29]. Although long suspected [1, 19], it has only recently
been demonstrated unequivocally that the parathyroid gland
belongs to this category, both in the rat [25], and in the human
[31]. In the adult rat, normal parathyroid cell turnover is about
50%/year, corresponding to a mean cell life span of about two
years [25]. In humans, the normal rate of parathyroid cell turnover
is about 5%/year, corresponding to a mean cell life span of about
20 years [311. Since adult parathyroid weight remains stable [11,
these low rates of cell gain must be balanced by equivalent rates
of cell loss by apoptosis, although this process has not yet been
detected in the parathyroid gland [25, 28].
The adult parathyroid gland not only has a rate of cell turnover
that is lower than in any other tissue in the body except nerve and
muscle, but it responds much less adequately than other tissues to
cell loss. The proliferative response to hemi-resection is much
more sluggish than in the thyroid gland [32], reflecting the
absence both of a trophic hormone and of whatever mechanisms
enable the liver and the kidney to undergo rapid regeneration [29,
30]. Consequently, changes in parathyroid cell number, in either
direction, can only occur very slowly. Apart from its obvious
physiological importance, the distinction between high and low
turnover tissues is also relevant to the behavior of cells in culture.
Regardless of their tissue of origin, cultured cells have an intrinsic
drive to proliferate rapidly until they reach confluence or are
deprived of serum. Such in vitro behavior is much closer to the in
vivo behavior for high than for low turnover tissues. Parathyroid
cells in culture have a doubling time of only one to two days [33],
much shorter even than during peak embryonic growth in vivo,
with doubling times of seven to ten days [1]. For this reason,
studies of growth in cultured parathyroid cells [34, 35] may be
quite misleading with respect to their in vivo proliferative behavior
in the adult organism.
The designation of a low turnover tissue as conditionally
renewing [291 implies that cell proliferation will increase above its
usual low level when more cells are needed. In endocrine glands,
the need for more cells is created by an increased demand for
hormone secretion that cannot be satisfied by the present number
of cells. The parathyroid gland has a hierarchy of mechanisms for
increasing hormone secretion by individual cells that operate over
progressively longer time scales [1—3, 20]: release of stored
hormone, decreased hormone degradation, and increased hor-
mone biosynthesis. There is also a mechanism, possibly unique to
the parathyroid gland, for recruitment of temporarily inactive
cells into activity [36]. The notion of a secretory cycle was
originally proposed on the basis of the ultramicroscopic distinc-
tion between light and dark chief cells [37], a distinction that
recent electron microscopists have dismissed as artifact [23]. But
the existence of a secretory cycle has been demonstrated unequiv-
ocally by applying the reverse hemolytic plaque assay to dispersed
parathyroid cells [36, 38]. This phenomenon is relevant to the
present discussion for two reasons. First, inability to prolong
indefinitely the period of secretory inactivity may underlie the
minimum non-suppressible rate of PTH secretion by the whole
gland [39], although this phenomenon may be of short duration in
view of the frequency with which circulating intact PTH levels are
undetectable in patients with non-parathyroid hypercalcemia [40].
Second, if the demand for increased PTH secretion is long
sustained, it can only be met by an increase in parathyroid cell
number, and cells that have temporarily interrupted hormone
secretion can most appropriately respond to a proliferative stim-
ulus [1].
Since hypocalcemia is the main circumstance that requires an
increase in PTH secretion, hypocalcemia should also he the main
stimulus to increased parathyroid cell proliferation. Although
there are some inconsistencies in the published data, this predic-
tion has been reasonably well confirmed [1]. Until recently the
most convincing results have been obtained with organ culture, in
which lower ambient calcium concentrations have been accompa-
nied by increased prevalence of both mitosis [41] and of S-phase
cells labeled with tritiated thymidine [42]. The paradoxical results
with cultured parathyroid cells were mentioned earlier [34, 35]. In
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very young rats, the increase in parathyroid volume in response to
dietary calcium restriction was due mainly to hypertrophy [231, but
with more severe hypocalcemia, the duration of secretory inactiv-
ity may be too short to permit entry into the cell cycle [1].
Parathyroid hyperplasia in response to calcium deficiency has
been inferred from increased weight and unchanged protein/DNA
ratio [431, but at the time of sacrifice the presumed increase in
DNA synthesis had subsided. More recently, phosphate adminis-
tration, which induces hypocalcemia, increased PTH secretion,
and increased serum calcitriol levels, has been found to increase
parathyroid cell proliferation and induce parathyroid hyperplasia
[24, 25]. The latter changes were not shown unequivocally to be
the result of hypocalcemia, but this appeared to be the most
plausible explanation, although phosphate also has a direct effect
on parathyroid cell proliferation, as well as on hormone secretion
[4, 6].
Another circumstance that may require an increase in PTH
secretion is calcitriol deficiency. Because of its many other effects,
maintenance of calcitriol production could be important for
reasons unrelated to its role in calcium homeostasis [44]. This is a
likely function for a subsidiary feedback loop, whereby a low
circulating calcitriol level increases PTH secretion independent of
calcium, and increased circulating PTH increases the activity of
the renal 1c-hydroxylase [7, 8, 20, 45]. For the same reason as for
prolonged hypocalcemia, prolonged calcitriol deficiency would be
expected to increase cell proliferation as well as hormone secre-
tion in the parathyroid gland, and some experimental evidence for
this relationship has been obtained [34, 35, 43, 45J. Hypocalcemia
stimulates parathyroid cell proliferation in part, by interacting
with a paracrine mechanism involving acidic FGF and its receptor
[46]. Whether calcitriol acts via the same system, or via a separate
mechanism such as the c-myc proto-oncogene [34], or whether
calcitriol has a generalized antiproliferative effect that is not
specific to parathyroid cells [45], is unclear. Increased cell prolif-
eration could also be linked directly to increased hormone
secretion, as in other endocrine glands [1].
INCREASED PARATHYROID CELL PROLIFERATION AND
HYPERPLASIA IN CHRONIC RENAL FAILURE
Based on the preceding analysis, it is likely that increased
parathyroid cell proliferation is a later consequence of whatever
factors lead to increased PTH secretion in renal failure. The
bimodal distribution of parathyroid weights [91 implies that mild
parathyroid hyperplasia occurs in most patients with chronic renal
failure, but that hyperplasia of sufficient severity to need parathy-
roid surgery develops only in a small minority. It seems reasonable
to attribute the former to the same abnormalities as the near-
universal parathyroid hormone hypersecretion, namely some
combination of mild hypocalcemia, hyperphosphatemia and cal-
citriol deficiency [1, 2, 7, 8], but some patients with early chronic
renal failure have PTH hypersecretion despite normal circulating
levels of both ionized calcium, phosphate and calcitriol [7, 8, 45,
47]. One possible explanation for this paradox is that in most
clinical studies, measurements are made on a single serum sample
obtained in the early morning fasting state, but it may require
multiple circadian samples to identify changes early in the disease
course. Whatever the explanation, which of the abnormalities
occurs first, and which is the most important, is uncertain for both
PTH hypersecretion and PT hyperplasia, and may differ between
patients for reasons unknown.
A good candidate for a factor which could lead to much more
severe parathyroid growth in a minority of patients is an increase
in PTH secretory set-point. Parathyroid cells with an increase in
set-point will respond to erroneously perceived hypocalcemia in
the same way as normal parathyroid cells respond to actual
hypocalcemia, with an increase in hormone secretion followed by
an increase in cell proliferation [1, 481. In unselected dialysis
patients, the secretory set-point is normal and does not increase
with the severity of hyperparathyroidism [49], but in many patients
needing surgical removal of parathyroid tissue, an increase of
secretory set-point has been found in dispersed cells obtained at
surgery [50], an abnormality even more evident in cells harvested
from nodular regions within the enlarged gland [51]. More
recently, reduced expression of the calcium sensing serpentine
receptor, the probable regulator of the secretory set-point [521,
has been found in such patients [53], although the mechanism is
unknown. In primary hyperparathyroidism, an increase in secre-
tory set-point has been proposed as an explanation for retardation
of tumor growth as the new clone of cells becomes large enough
to raise the patient's serum calcium to the new set-point, so that
growth is asymptotic or Gompertzian in character [1, 48]. But in
severe secondary hyperparathyroidism, because of the many fac-
tors in chronic renal failure that impair the effectiveness of PTH
in raising plasma calcium [7, 8], the increase in total hormone
secretion necessary to attain the new set-point can be achieved
only with an enormous increase in the number of secretory cells
[13].
An increase in secretory set-point due to reduced calcium
receptor expression [53] also provides a plausible explanation for
the development of hypercalcemia in a minority of patients with
severe secondary hyperparathyroidism [13]. In such patients, both
parathyroid weight [54, 55], and the rate of DNA synthesis [13]
are positively correlated with both PTH levels and plasma cal-
cium, indicating that it is not hormone secretion but rather growth
that has become autonomous, since plasma calcium is behaving as
the dependent, rather than as the independent, variable [1, 13], a
conclusion supported by the sustained restoration of normocalce-
mia after surgery [13, 55]. The birth rate of new cells is higher than
in primary parathyroid adenomas, and does not slow down as in
primary hyperparathyroidism, but remains as rapid as when the
glands first began to enlarge soon after the onset of renal failure
[13]. Calcitriol administration reduces PTH biosynthesis, but its
effect on the parathyroid secretory set-point is inconsistent [56].
However, if progressive resistance to the hypercalcemic effect of
PTH is combined with an increase in secretory set-point, the
target of the parathyroid cells is continually receding instead of
remaining stable. This phenomenon will be augmented by the
lower levels of calcitriol receptors in parathyroid cells from uremic
patients [57], and consequent lesser responsiveness of these cells
to calcitriol [58].
Further insight into the mechanism of the growth disorder is
provided by the histologic distinction between diffuse and nodular
hyperplasia. The nodules consist of cells that are more closely
packed together with larger nuclei and a greater prevalence of cell
cycle markers [59, 60], more cycling cells by flow cytometry [61],
greater depletion of calcitriol receptors [57], and, as mentioned
earlier, higher secretory set-point [51]. Detailed histochemical
and immunocytochemical studies indicate similarity in gene ex-
pression between the cells in each nodule, but differences between
nodules [62]. Each nodule could have arisen from a different
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single cell or, more likely, from a group of adjacent cells that
themselves were the clonal descendants of a founding cell present
during embryonic development, and so constitute a "patch" [63].
In some cases, parathyroid glands removed from such patients
have been reported as monoclonal, implying an origin from a
single mutant cell [64]. The biochemical determination of clonal-
ity, based on polymorphism for X-linked DNA sequences, is less
rigorous than the morphologic determination of clonality, based
on studying gene expression in individual cells [Parfitt, unpub-
lished data]. Consequently, the proportion of the original hyper-
plastic gland that contributed to the tumor, and the relationship
between such a tumor and the hyperplastic nodules previously
described is unclear. It is possible that each nodule is already a
monoclonal tumor, but more likely that such tumors arise at a
later time within one or more nodules.
The parathyroid growth response in chronic renal failure
progresses through several stages. Diffuse, polyclonal, secondary
hyperplasia is initiated by hypocalcemia and becomes more severe
as the result of calcitriol deficiency. Because of reduced calcium
receptor expression and consequent increase in secretory set-
point in some cells, the hyperplasia becomes nodular and multi-
clonal, and the glandular enlargement asymmetric and often
accompanied by hypercalcemia. The next stage is the emergence
of an adenoma as the expression of a mutation in one of the cells
in a nodule. Since mutations occur preferentially, or perhaps
exclusively, in dividing cells [Parfitt, unpublished data], the prob-
ability of a mutation would have been increased by the prior
increase in the rate of cell proliferation [1, Parfitt, unpublished
data]. This sequence is referred to as tertiary hyperparathyroid-
ism, a term best reserved for the disorder that combines in its
etiology the hyperplasia of secondary hyperparathyroidism with
the monoclonality of primary hyperparathyroidism [1]. In some
cases, there may be loss of a tumor suppressor gene on chromo-
some-il, a molecular defect found also in some primary parathy-
roid adenomas [66]. In other cases, the mutation may be respon-
sible for the increase in secretory set-point, as has been proposed
for primary hyperparathyroidism [48]. The final and least common
stage is malignant transformation leading to parathyroid carci-
noma, an event that seems to occur with unusual frequency in
patients on long-term hemodialysis [1], possibly because of defec-
tive DNA repair [67], as well as increased cell proliferation.
THERAPEUTIC IMPLICATIONS OF PARATHYROID
GROWfH
There is a long-standing and pervasive assumption that if the
initial stimulus to cell proliferation is removed, the enlarged
parathyroid glands in patients with renal failure will eventually
return to their previous size. This assumption is based on misin-
terpretation of cross-sectional differences in parathyroid size [271
and of ultrastructural indices of reduced hormone secretion and
release [68], and erroneous analogies with other endocrine glands
[1]. Nevertheless, it remains uncertain that a non-destructive
increase in cell loss is possible in human parathyroid glands.
Synthetic compounds that activate the serpentine calcium sensing
receptor reduce the secretory set-point and inhibit PTH secretion
[69]. As expected from the preceding discussion, parathyroid cell
size is reduced, but cell number is unaffected [70]. Such com-
pounds could be useful to counteract the effect of reduced
serpentine receptor expression, and to prevent an additional
stimulus to hyperplasia, but are unlikely to reverse hyperplasia
once it has occurred. The absence of a trophic hormone may limit
the capacity of the parathyroid gland for involution, as well as for
growth, but even in the thyroid gland, regression of hyperplasia is
less frequent and less complete than is commonly assumed [26].
In low turnover conditionally renewing tissues, cell loss occurs
by apoptosis [71]. If the duration of DNA fragmentation is only 30
minutes [721, its prevalence in the normal human parathyroid
gland would be only about 1/350,000 cells. Apoptosis could not be
detected even in the rat parathyroid [25, 28], in which its
prevalence should be ten times greater, probably because too few
cells were examined. Indirect evidence for parathyroid apoptosis
was obtained in three-month-old vitamin D deficient chicks, in
which vitamin D replacement was rapidly followed by a parallel
reduction in parathyroid weight, protein and DNA content, but
there was no direct evidence for reduction in cell number [73].
Apoptosis must occur in the human parathyroid gland, or else
parathyroid size would increase about seven-fold between ages 30
and 70 years (1.05° = 7.04), but why and when it occurs, and
whether the normal rate can be increased, are completely un-
known. If cell birth rate fell to zero, and apoptosis continued at
the normal rate of 5%/year, parathyroid cell number would fall by
about 40% in ten years and 3.0 g of surplus parathyroid tissue
would shrink to 0.5 g in about 35 years.
These extremely pessimistic calculations concerning the possi-
bilities of parathyroid involution have several important implica-
tions for therapy. First, it is clear that even more emphasis needs
to be placed on the prevention of parathyroid hyperplasia in early
chronic renal failure [45, 58, 74]. Since PT hyperplasia is always a
later response than PTH hypersecretion to the same stimuli, if
PTH levels are increased more than twofold for more than six
months, it is safe to assume that some PT hyperplasia has already
occurred. Prevention of PTI-I hypersecretion, which is easy to
monitor, will prevent PT hyperplasia, which at present is impos-
sible to monitor in its early stages. Second, once severe hyper-
parathyroidism has been allowed to occur, then however success-
ful medical treatment may be in reducing PTH hypersecretion, it
should be assumed, in the absence of evidence to the contrary,
that no significant reduction in parathyroid cell number will have
occurred. Consequently, the dose of calcitriol found necessary to
maintain a desirable degree of reduction in PTH secretion will
need to be continued indefinitely. Furthermore, unless the in-
creased rate of parathyroid cell proliferation can be reduced to
normal, something not yet shown to be possible, the suppressive
dose of calcitriol will eventually need to be further increased. In
one of the few prospective controlled clinical trials in this field,
there was no significant difference in the response to oral and
intravenous calcitriol given in the same dose, and after 36 weeks
there was no change in ultrasonographically determined parathy-
roid size or dynamic indices of PTH hypersecretion, regardless of
the route of administration [75].
An important unresolved issue is whether it is possible to
stimulate apoptosis in parathyroid cells and so accelerate involu-
tion. There are precedents for this possibility in other endocrine
glands. In many pituitary tumors, dopamine agonists such as
bromocryptine can reduce size as well as hormone secretion [76].
Furthermore, in several kinds of tissue that are hyperplastic as a
result of endocrine stimulation, abrupt withdrawal of the relevant
trophic factor can induce apoptosis [71]. If calcitriol is a negative
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parathyroid growth factor, then a large abrupt rise in its concen-
tration might have the same effect as a large abrupt fall in the
concentration of a positive growth factor. There have been several
reports that pulse administration of calcitriol in high dose (8 j.g)
may be followed by substantial reduction (about 40%) of para-
thyroid volume determined ultrasonographically [13, 77]. Calcit-
riol may induce parathyroid apoptosis in rats [78], but no histo-
logic verification has been reported in the clinical studies, and the
shrinkage could reflect reductions in cell size and in vascularity,
rather than in cell number. Furthermore, in the controlled trial
previously referred to [75], calcitriol was administered in pulse
fashion, although the maximum dose of 4 xg may have been too
small to achieve the effects reported with a higher dose.
Disordered parathyroid growth also has implications for the
surgical management of hyperparathyroidism. The first procedure
carried out was subtotal parathyroidectomy leaving only a portion
of the smallest gland [79]. Much later an alternative procedure
was introduced, namely total parathyroidectomy and autotrans-
plantation of tissue into the forearm [80]. The advantages claimed
were that monitoring of the function of the autograft was easier
because its venous drainage was accessible, and if the remnant
grew rapidly enough for severe hyperparathyroidism to recur,
re-exploration would be easier [81]. More recently, total parathy-
roidectomy without autotransplantation has been recommended
[82]. The prolonged maintenance of normocalcemia that some-
times follows this procedure is presumed to depend on parathy-
roid embryonic rests that were too small or too aberrant in
location to be removed. Each of these procedures has its propo-
nents and opponents, but the long-term results of each are quite
similar [83]. Whatever procedure is used, it is important to avoid
spillage of abnormal cells, which may lead to recurrence due to
parathyromatosis [83]. More important than the choice between
procedures is the timing, regardless of which one is adopted.
Parathyroidectomy is usually considered only as a last resort
after protracted attempts at securing adequate suppression of
PTH secretion by medical means have failed. This attitude reflects
the misconception that only the function of the glands, rather than
their size, is an appropriate therapeutic target. An estimate of
parathyroid size, in conjunction with an estimate of likely life
expectancy, would provide a more rational basis for the timing of
parathyroid surgery [15, 58]. If expert and well validated ultra-
sonographic examination is unavailable, then an index of PTH
suppressibility by calcium would be a reasonable surrogate [16]. If
parathyroidectomy was carried out before loss of calcium receptor
expression, increase in secretory set-point and development of
nodular hyperplasia, subtotal parathyroidectomy, followed by
calcitriol to control the secretion and growth of the parathyroid
remnant, should be effective and rarely followed by recurrence of
severe hyperparathyroidism. Conversely, if parathyroidectomy is
delayed until the patient has severe osteitis fibrosa or hypercal-
cemia, then nodular hyperplasia or adenoma formation can be
presumed. If total parathyroidectomy is chosen, it makes sense to
transplant only tissue harvested from the smallest and least
nodular gland, or, if all glands are nodular, from an internodular
region [81, 84]. Indiscriminate choice of transplanted tissue is
more likely to be followed by aggressive and even invasive growth
[85]. Although this is clear in principle, the best method of
ultra-operative selection of cells with the lowest potential for
proliferation remains to be established [861.
A final issue is the management of persistent post-transplant
hypercalcemia. Although this may have several possible causes,
persistent hyperparathyroidism is the most likely [19, 87, 88]. This
is now less common than in the past, presumably because control
of PTH hypersecretion has improved, but still occurs in about 5%
of patients [88, 891, and hypercalcemia of unchanged severity can
continue for ten years or more [19]. Restoration of normal renal
function should arrest further increase in parathyroid cell number,
and lead to complete reversal of hypertrophy. But if stable
hypercalcemia lasts for more than one year after renal transplan-
tation, its permanence should be assumed, and surgical treatment
should be considered [88, 90]. For reasons discussed previously,
the rate of involution due to apoptosis will be too slow to be of
clinical importance. Patients with post-transplant hypercalcemia
are often relatively young, they have usually had substantial loss of
appendicular cortical bone before transplantation [87], and they
only have a single functioning kidney. Any one of these three
circumstances would usually be regarded as a reasonable indica-
tion for surgery in a patient with primary hyperparathyroidism,
and the concurrence of all three would, in the judgement of most
endocrinologists, make surgery mandatory. There may be several
good reasons for postponing or avoiding parathyroid surgery in
patients with sustained post-transplant hypercalcemia, but expec-
tation that the condition will resolve spontaneously is not among
them.
Reprint requests to A. Michael Parfitt, M.D., UAMS Hospital, Endocrinol-
ogy and Metabolism, Slot 587, 4301 W Markham Street, Little Rock,
Arkansas 72205-7199, USA.
REFERENCES
1. PARFITIT AM: Parathyroid growth: Normal and abnormal, in The
Parathyroids—Basic and Clinical Concepts, edited by BILEZIKIAN JP
New York, Raven Press, 1994, pp 373—405
2. BROWN EM: Mechanism underlying the regulation of parathyroid
hormone secretion in vivo and in vitro. Curr Opin Nephrol Hypertens
2:541—551, 1993
3. PARFITr AM: Calcium homeostasis, in Handbook of experimental
Pharmacology (vol 107), Physiology and Pharmacology of Bone, edited
by MUNDY GR, MARTIN TJ, Heidelberg, Springer-Verlag, 1993, pp
1—65
4. SLATOPOLSKY E, FINCH J, DENDA M, RIl-FER C, ZHONG M, Dusso A,
MACDONALD PN, BROWN AJ: Phosphorus restriction prevents para-
thyroid gland growth. High phosphorus directly stimulates PTH
secretion in vitro. J Clin Invest 97:2534—2540, 1996
5. ALMADEN Y, CANALEJO A, HERNANDEZ A, BALLESTEROS E, GARCIA-
NAVARRO 5, TORRES A, RODRIGUEZ M: Direct effect of phosphorus
on PTH secretion from whole rat parathyroid glands in vitro. J Bone
Miner Res 11:970—976, 1996
6. DENDA M, FINCH J, SLATOPOLSKY E: Phosphorus accelerates the
development of parathyroid hyperplasia and secondary hyperparathy-
roidism in rats with renal failure. Am J Kid Dis 28:596—602, 1996
7. SLATOPOLSKY E, DELMEZ J: Pathogenesis of secondary hyperparathy-
roidism. Am J Kidney Dis 23:229—236, 1994
8. DRUEKE TB: The pathogenesis of parathyroid gland hyperplasia in
chronic renal failure. Kidney mt 48:259—272, 1995
9. STANBURY SW, LUMB GA: Parathyroid function in chronic renal
failure. Q J Med 35:1—23, 1966
10. PARFITF AM: The actions of parathyroid hormone on bone. Relation
to bone remodelling and turnover, calcium homeostasis and metabolic
bone disease. III. PTH and osteoblasts, the relationship between bone
turnover and bone loss, and the state of the bones in primary
hyperparathyroidism. Metabolism 25:1033—1069, 1976
11. LLOYD HM: Primary hyperparathyroidism: An analysis of the role of
the parathyroid tumor. Medicine 47:53—71, 1968
12. KRAUSE MW, HEDINGER CE: Pathologic study of parathyroid glands
in tertiary hyperparathyroidism. Hum Pathol 16:772—784, 1985
8 Parfitt: The hypeiparathyroidism of CRF
13. LLOYD HM, PARFI-J-r AM, JAcoBI JM, WILLGOSS DA, CRASWELL PW,
PETRIE JJB, BOYLE PD: The parathyroid glands in chronic renal
failure: A study of their growth and other properties, based on findings
in hypercalcemic patients. J Lab Clin Med 114:358-367, 1989
14. MALLEYrE LE, KH0URI K, ZENGOTITA H, HOLLIS BW, MALINI S:
Lithium treatment increases intact and mid region parathyroid hor-
mone and parathyroid volume. J Clin Endocrinol Metab 68:654—660,
1989
15. FUKAGAWA M, KJTAOKA M, Yi H, FUKUDA N, MATSUMOTO T, OGATA
E, KUROKAWA K: Serial evaluation of parathyroid size by ultrasonog-
raphy is another useful marker for the long-term prognosis of
calcitriol pulse therapy in chronic dialysis patients. Nephron 68:221—
228, 1994
16. INDRIDASON OS, HEATH H III, KHOSLA 5, Yo-ie DA, QUARLES LD:
Non-suppressible parathyroid hormone secretion is related to gland
size in uremic secondary hyperparathyroidism. Kidney mt 501663—
1671, 1996
17. Girres RF, RADDE IC: Experimental hyperparathyroidism from
multiple isologous parathyroid transplants: homeostatic effect of
simultaneous thyroid transplants. Endocrinology 78:1015—1022, 1966
18. PARFITr AM: A theoretical model of the relationship between para-
thyroid cell mass and plasma calcium concentration in normal and
uremic subjects: An analysis of the concept of autonomy and specu-
lations on the mechanism of parathyroid hyperplasia. Arch Intern Med
124:269—273, 1969
19. PARFITF AM: Hypercalcemic hyperparathyroidism following renal
transplantation: Differential diagnosis, management, and implications
for cell population control in the parathyroid gland. Miner Electrol
Metab 8:92—1 19, 1982
20. BROWN EM: Homeostatic mechanisms regulating extracellular and
intracellular calcium metabolism, in The Parathyroids, edited by
BILEZIK1AN JP, LEVINE MA, MARCUS R, New York, Raven Press, Ltd.,
1994, pp:15—54
21. ALTENAHR E, ARPS H, MONTZ R, DORN G: Quantitative ultrastruc-
tural and radioimmunologic assessment of parathyroid gland activity
in primary hyperparathyroidism. Lab Invest 31:303—312, 1979
22. MCCARRON DA, MUTHER RS, LENFESTY B, BENNETr WM: Parathy-
roid function in persistent hyperparathyroidism: relationship to gland
size. Kidney mt 22:662—670, 1982
23. WERNERSON A, SVENSSON 0, REINHOLT FP: Quantitative and three-
dimensional aspects of the rat parathyroid gland in normo-, hypo-, and
hypercalcemia. Microsc Res Tech 32:129—147, 1995
24. WANG Q, PALOYAN E, PARFITIT AM: Phosphate administration in-
creases both size and number of parathyroid cells in adult rats. Calcif
Tissue mt 58:40—44, 1996
25. WANG Q, PALNITKAR S, PARFITIT AM: Parathyroid cell proliferation in
the rat. Effect of age, and of phosphate administration and recovery.
Endocrinol 137:4558—4562, 1996
26. STRUDER H, DERWAHL M: Mechanisms of nonneoplastic endocrine
hyperplasia—a changing concept: A review focused on the thyroid
gland. Endocr Rev 16:411—426, 1995
27. ST0ERK HC, CARNES WH: The relation of the dietary Ca:P ratio to
serum Ca and to parathyroid volume. J Nutr 29:43—50, 1945
28. NAVEH-MANY T, RAHAMIMOV R, LIvNI N, SILVER J: Parathyroid cell
proliferation in normal and chronic renal failure rats. The effects of
calcium, phosphate, and vitamin D. J Clin Invest 96:1786—1793, 1995
29. WRIGHT N, ALISON M (editors): The Biology of Epithelial Cell Popu-
lations. Oxford, Clarendon Press, 1984
30. BASERGA R (editor): The Biology of Cell Reproduction. Cambridge,
Harvard University Press, 1985
31. WANG 0, PALNITKAR S, PARFITF AM: The basal rate of cell prolifer-
ation in normal human parathyroid tissue: implications for the
pathogenesis of hyperparathyroidism. Clin Endocrinol (in press)
32. LADIZESKY M, DIAZ MC, ZENI S, RoMEo HE, ARDINALI DP,
MAUTALEN CA: Compensatory parathyroid hypertrophy after hemip-
arathyroidcctomy in rats feeding a low calcium diet. Calcif Tissue mt
48:63—67, 1991
33. BRANDI ML, FITZPATRICK LA, CooN HG, AURBACH GD: Bone
parathyroid cells: Cultures maintained for more than 140 population
doublings. Proc NatlAcad Sci USA 83:1709—1713, 1986
34. KREMER R, BOLIVAR I, GOI,TZMAN D, HENOY GN: Influence of
calcium and 1,25-dihydroxycholecalciferol on proliferation and proto-
oncogene expression in primary cultures of bovine parathyroid cells.
Endocrinol 125:935—941, 1989
35. CORREZE M-C, GOGUSEV J, BOURDEAU A, SARFATI E, DRUEKE TB: In
vitro regulation of PTH synthesis/secretion and parathyroid (PT) cell
[3Hj-thymidine uptake by calcium and calcitriol in human PT tissue.
(abstract) JAm Soc Nephrol 6:958, 1995
36. FITZPATRICK LA, LEONG DA: Individual parathyroid cells are more
sensitive to calcium than a parathyroid cell population. Endocrinol
126:1720—1727, 1990
37. SHANNON WA, ROTH SI: An ultrastructural study of acid phosphatase
activity in normal, adenomatous and hyperplastic (chief cell type)
human parathyroid glands. Am J Pathol 77:493—501, 1974
38. SUN F, RITCHIE C, HASSAGER C, MAERCKLEIN F, FITZPATRICK L:
Heterogeneous response to calcium by individual parathyroid cells.
J Clin Invest 91:595—601, 1993
39. MAYER GP, HABENER JF, Porrs JT JR: Parathyroid hormone secre-
tion in vivo. Demonstration of a calcium-independent, nonsuppress-
ible component of secretion. J Clin Invest 57:678—683, 1976
40. NUSSBAUM SR, Porrs JT JR: Advances in immunoassays for parathy-
roid hormone. Clinical applications to skeletal disorders of bone and
mineral metabolism, in The Parathyroids, BILEZIKIAN JP, LEVINE MA,
MARCUS R, New York, Raven Press, Ltd., 1994, pp 157—184
41. RAIsz LG: Regulation by calcium of parathyroid growth and secretion
in vitro. Nature 197:1115—1117, 1963
42. LEE MJ, ROTH SI: Effect of calcium and magnesium on deoxyribonu-
cleic acid synthesis in rat parathyroid glands in vitro. Lab Invest
1:72—79, 1975
43. SZABO A, MERKE J, BEIER E, MALL G, RITZ E: 1,25(OH)2 vitamin D3
inhibits parathyroid cell proliferation in experimental uremia. Kidney
Int 35:1049—1056, 1989
44. WALTERS MR: Newly identified actions of the vitamin D endocrine
system. Endocr Rev 13:719—764, 1992
45. RITZ E, STEFANSKI A: Endocrine disturbances of calcium metabolism
in uremia: Renal causes and systemic consequences. Kidney mt
49:1765—1768, 1996
46. SAKAGUCHI K: Acidic fibroblast growth factor autocrine system as a
mediator of calcium-regulated parathyroid cell growth. J Biol Chem
34:24554—24562, 1992
47. PIT-ITS TO, PntINo BH, MITRO R, CHEN TC, SEGRE GV, GREENBERG
A, PUSCHETI' JB: Hyperparathyroidism and 1,25-dihydroxyvitamin D
deficiency in mild, moderate, and severe renal failure. J Clin Endocri-
nol Metab 67:876—88 1, 1988
48. PARFITr AM, BRAUNSTEIN GD, KATZ A: Radiation-associated hyper-
parathyroidism: Comparison of adenoma growth rates, inferred from
weight and duration of latency, with prevalence of mitosis. J Clin
EndocrinolMetab 77:1318—1322, 1993
49. GOODMAN WG, BELIN T, GALES B, JUPPNER H, SEGRE GV, SALUSKY
IB: Calcium-regulated parathyroid hormone release in patients with
mild or advanced secondary hyperparathyroidism. Kidney Int 48:1553—
1558, 1995
50. BROWN EM, WILKSON RE, EASTMAN RC, PALLOTITA J, MARYNICK SP:
Abnormal regulation of parathyroid hormone release by calcium in
secondary hyperparathyroidism due to chronic renal failure. J Clin
Endocrinol Metab 54:172—179, 1982
51. WALLFELT CH, LARSSON R, GYLFE R, LJUNGtIALL E, RASTAD 5,
AKERSTROM G: Secretory disturbance in hypcrplastic parathyroid
nodules of uremic hypcrparathyroidismm: implication for parathyroid
autotranspiantation. World] Surg 12:431—438, 1988
52. Ho C, CONNER DA, POLLAK MR, LADD DJ, KIFOR 0, WARREN HB,
BROWN EM, SEIDMAN JG, SEIDMAN CE: A mouse model of human
familial hypocalciuric hypercalcemia and neonatal severe hyperpara-
thyroidism. Nature Genet 11:389—394, 1995
53. KIFOR 0, MOORE FD JR, WANG P, GOLDSTEIN M, VASSILEV P, KIFOR
I, HEBERT SC, BROWN EM: Reduced immunostaining for the extra-
cellular Ca2 -sensing receptor in primary and uremic secondary
hyperparathyroidism. J Clin Endocrinol Metab 81:1598—1606, 1996
54. MALMAEUS J, GRIMELIUS L, JOHANSSON H, AKERSTROM G, LiEN-
GIIALL S: Parathyroid pathology in hyperparathyroidism secondary to
chronic renal failure. Scand J Urol Nephrol 18:157—166, 1984
55. JOIINSON WJ, MCCARTHY JT, VAN HEERDEN JA, STERIOFF S, GRANT
CS, KA0 PC: Results of subtotal parathyroidectomy in hemodialysis
patients. Am J Med 84:23—32, 1988
Parfitt: The hype,'parathyroidism of CRF 9
56. FELSENFELD AJ, LLACH F: Parathyroid gland function in chronic renal
failure. Kidney mt 43:771—789, 1993
57. FUKUDA N, TANAKA H, TOMINAGA Y, FUKAGAWA M, KUROKAWA K,
SEIN0 Y: Decreased 1,25-dihydroxyvitamin D3 receptor density is
associated with a more severe form of parathyroid hyperplasia in
chronic uremie patients. J Clin Invest 92:1436—1443, 1993
58. FUKAGAWA M, FUKUDA N, Yt H, KUROKAWA K: Resistance of
parathyroid cell to calcitriol as a cause of parathyroid hyperfunetion in
chronic renal failure. (Editorial Comments) Nephrol Dial Transplant
10:316—319, 1995
59. DE FKANcIsco AM, ELLIS HA, OWEN JP, CASSIDY MJ, FARNDON JR,
WARD MK, KERR DN: Parathyroidectomy in chronic renal failure.
QJMed 55:289—315, 1985
60. LODA M, LIPMAN J, CUKOR B, BUR M, KWAN P, DELELLIS RA:
Nodular foci in parathyroid adenomas and hyperplasias: An immuno-
histochemieal analysis of proliferative activity. Hum Pathol 25:1050—
1056, 1994
61. TOMINAGA Y, GRIMELIUS L, FALKMER UG, JOHANSSON H, FALKMER
S: DNA ploidy pattern of parathyroid parenchymal cells in renal
secondary hyperparathyroidism with relapse. Anal Cell Pathol 3:325—
333, 1991
62. OKA T, YosHIoKA T, SHRESTHA GR, K0IDE T, SONODA T, HosoKAwA
S, ONOE K, SAKURAI M: Immunohistoehemical study of nodular
hyperplastie parathyroid glands in patients with secondary hyperpara-
thyroidism. Virchows Arch 413:53—60, 1988
63. THOMAS GA, WILLIAMS D, WILLIAMS ED: The elonal origin of thyroid
nodules and adenomas. Am J Pathol 134:141—147, 1989
64. ARNOLD A, BROWN MF, URENA P, GAZ RD, SARFATI E, DRUEKE TB:
Monoclonality of parathyroid tumors in chronic renal failure and in
primary parathyroid hyperplasia. J Gun Invest 95:2047—2053, 1995
65. Deleted in proof.
66. FALCHETFI A, BALE AE, AMOROSI A, BORDI C, CIccI-Il P. BANDINI 5,
MARX SJ, BRANDI ML: Progression of uremie hyperparathyroidism
involves allelic loss on chromosome 11. J Clin Endocrinol Metab
76:139—144, 1983
67. MALACHI T, ZEVIN D, GAFTER U, CHAGNAC A, SLOR H, LEVI J: DNA
repair and recovery of RNA synthesis in uremie patients. Kidney mt
44:385—389, 1993
68. ROTH SI: Recent advances in parathyroid gland pathology. Am J Med
50:612—622, 1971
69. SILVERBERG SI, THYS-JACOBS 5, LOCKER FG, SANGUINE1TI EL, MAR-
RIOT TB, BILEZIKIAN JP: The effect of the caleimimetic drug NPS
R-568 on parathyroid hormone secretion in primary hyperparathy-
roidism. J Bone Miner Res 11(Suppl 1):S116, 1996
70. CHIN J, MILLER SC, NEMETH EF, FOX J: The caleimimetic compound
NPS R-568 reduces parathyroid cell and gland size but not cell
number in rats with chronic renal insufficiency. (abstract) J Bone Miner
Res 11(Suppl 1):S121, 1996
71. KERR JFR, SEARLE J, HARMON By, BISHoP CJ: Apoptosis, in
Perspectives on Mammalian Cell Death, edited by POTTEN CS, Oxford,
Oxford University Press, 1987, pp 93—128
72. MANJO G, J0RIs I: Apoptosis, oneosis, and necrosis—An overview of
cell death. Am J Pathol 146:3—15, 1995
73. HENRY HL, TAYLOR AN, NORMAN AW: Response of chick parathy-
roid glands to the vitamin D metabolites, 1,25-dihydroxycholecalcif-
erol and 24,25-dihydroxyeholecalciferol. J Nutr 107:1918—1926, 1977
74. Yt H, FIJKAGAWA M, YAMATO H, KIMAGAI M, WATANABE T, KURO-
KAWA K: Prevention of enhanced parathyroid hormone secretion,
synthesis and hyperplasia by mild dietary phosphorus restriction in
early chronic renal failure in rats: Possible direct role of phosphorus.
Nephron 70:242—248, 1995
75. QUARLES LD, YOHAY DA, CARROLL BA, SPRITZER CE, MINDA SA,
BARTHOLOMAY D, LOBAUGH BA: Prospective trial of pulse oral versus
intravenous ealcitriol treatment of hyperparathyroidism in ESRD.
Kidney mt 45:1710—1721, 1994
76. BEVAN JS, WEBBSTER J, BURKE CW, SCANLON MF: Dopamine
agonists and pituitary tumor shrinkage. Endocr Rev 13:220—240, 1992
77. FUKAGAWA M, OKAZAKI R, TAKANO K, KANAME S-Y, OGATA E,
Krl'AoKA M, HARADA S-I, SEKINE N, MATSUMOTO T, KUROKAWA K:
Regression of parathyroid hyperplasia by caleitriol-pulse therapy in
patients on long-term dialysis. N EngI J Med 323:421—422, 1990
78. FUKAGAWA M, Yl H, KUROKAWA K: Calcitriol induces apoptosis of
hyperplastie parathyroid cells in uremie rats. JAm Soc Nephrol 2:635,
1991
79. STANBURY SW, LUMB GA, NICHOLSON WF: Elective subtotal para-
thyroidectomy for renal hyperparathyroidism. Lancet i:793—799, 1960
80. WELLS SA, GUNNELLS JC, SHELBURNE JD, SCHNEIDER AB, SHER-
WOOD LM: Transplantation of parathyroid glands in man: Clinical
indications and results. Surgery 78:34—44, 1975
81. TOMINAGA Y, TANAKA Y, SATO K, NUMANO M, UCHIDA K, FALKMER
U, GRIMELIUS L, JOHANSSON H, TAKAGI H: Recurrent renal hyper-
parathyroidism and DNA analysis of autografted parathyroid tissue.
World JSurg 16:595—603, 1992
82. KAYE M, ROSENTHAL L, HILL RO, TABAH Ri: Long-term outcome
following total parathyroideetomy in patients with end-stage renal
disease. Clin Nephrol 39:192—197, 1993
83. STEHMAN-BREEN C, MUIRI-IFAD N, THORNINO D, SHERRARD D:
Secondary hyperparathyroidism complicated by parathyromatosis.
Am J Kid Dis 28:502—507, 1996
84. OHTA K, MANABE T, KATAGIRI M, HARADA T: Expression of prolif-
erating cell nuclear antigens in parathyroid glands of renal hyperpara-
thyroidism. World J Surg 18:625—629, 1994
85. ELLIS HA: Fate of long-term parathyroid autografts in patients with
chronic renal failure treated by parathyroidectomy: A histopatholog-
ical study of autografts, parathyroid glands and bone. Histopathology
13:289—309, 1988
86. ABBONA GC, PAPOTFI M, GASPARRI G, BUSSOLATI G: Recurrence in
parathyroid hyperplasias owing to secondary hyperparathyroidism is
predicted by morphological patterns and proliferative activity values.
Endocrine Pathol 7:55—61, 1996
87. PARFITr AM: Are bone problems of dialysis patients always solved by
renal transplantation? in A CPC Series: Cases in Metabolic Bone
Disease 1, No. 4, New York, Medical Projects Inc., 1986
88. JULIAN BA, QUARLES LD, NIEMANN KMW: Musculoskeletal compli-
cations after renal transplantation: Pathogenesis and treatment. Am J
Kid Dis 19:99—120, 1992
89. STRAFFEN AM, CARMICHAEL DJS, FAIRNEY A, HULME B, SNELL M:
Calcium metabolism following renal transplantation. Ann Cliii Bio-
chem (UK) 31:125—128, 1994
90. PUNCH JD, THOMPSON NW, MERION RM, VAN HEERDEN JA, SCHU-
LAK JA, BERNE TV: Subtotal parathyroidectomy in dialysis-dependent
and post-renal transplant patients: A 25-year single-center experience.
Arch Suig 130:538—543, 1995
